Compare BridgeBio Pharma Inc (BBIO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs BlackRock TCP Capital Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while BlackRock TCP Capital Corp trades at $3.93 (market cap $331.42M). The key difference: BridgeBio Pharma Inc is far larger — about 50.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.24% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TCPC | |
|---|---|---|
Market Cap | $16.61B | $331.42M |
Sector | Health | Financials |
52-Week High | $90.17 | $7.26 |
52-Week Low | $47.29 | $3.13 |
Enterprise Value | $18.16B | — |
Dividend Yield | — | 19.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TCPC trades at $4.11, up 5.38% in 24 hours, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a net income margin of 118.75% reflecting significant losses relative to revenue.
The outlook is mixed: strategic actions like portfolio sales and dividend payments ($0.17 per share) support value, but persistent losses and class action lawsuits pose risks. Analyst consensus leans hold, with 30.77% buy ratings, indicating cautious optimism amid financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
